source
- Spyre Therapeutics reports SPY072 fails psoriatic arthritis trial as Ideaya halts eye cancer studySpyre Therapeutics announced that its long‑acting anti‑TL1A candidate, SPY072, did not meet the primary endpoints in a psoriatic arthritis trial. The result adds to recent setbacks for Spyre in ot…
- Novo and Pfizer say MFN pricing agreements remain unchanged despite Democratic gains in CongressOn their third‑quarter earnings calls, the CEOs of Novo Nordisk and Pfizer said the Most Favored Nation drug‑pricing contracts they signed under the previous administration are still in effect and…